Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura

European Journal of Haematology

Volumn 86, Issue 3, 2011, Pages 256-259

  Clausen, Michael R ^a   Segel, Erik ^a   Brandsborg, Margrethe ^b   Damore, Francesco ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b RANDERS REGIONAL HOSPITAL   (Denmark)

Author keywords

Chronic immune thrombocytopenic purpura; Immune thrombocytopenic purpura; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; DRUG MEGADOSE; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LABORATORY TEST; MALE; MONOTHERAPY; PRIORITY JOURNAL; RELAPSE; REMISSION; SPLENECTOMY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; SELF TOLERANCE; SPLENECTOMY; TIME FACTORS;

EID: 79951643987     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01561.x     Document Type: Article

References (13)

1. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664-72.
2. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613-26.
3. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
4. Ahrens N, Kingreen D, Seltsam A, Salama A. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 2001;114:244-5.
5. Perotta P, Sunnemberg JS, Ratanatharathorn V. Rituxan in the treatment of chronic idiopathic thrombocytopenia purpura (ITP). Blood 1999;94:49a.
6. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
7. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
8. Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V, Filì C, Tani M, Baccarani M, Fanin R. Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006;34:571-2.
9. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275-80.
10. Semple JW, Provan D, Garvey MB, Freedman J. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 2010;17:590-5.
11. Cines DB, Liebman HA. The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am 2009;23:1155-61.
12. Simanek R, Panzer S, Lechner K, Pabinger I. Late spontaneous remissions in severe adult autoimmune thrombocytopenia. Ann Hematol 2007;86:705-10.
13. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-13.